NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials.

Property Value
dbo:abstract
  • NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. (en)
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-14 07:53:26Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 54219225 (xsd:integer)
dbo:wikiPageLength
  • 2970 (xsd:integer)
dbo:wikiPageModified
  • 2019-04-05 17:52:30Z (xsd:date)
dbo:wikiPageOutDegree
  • 18 (xsd:integer)
dbo:wikiPageRevisionID
  • 891103186 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdfs:comment
  • NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD). As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials. (en)
rdfs:label
  • NNI-351 (en)
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of